Ru Chih Huang

Title: Innovations of Ru Chih Huang in Cancer Treatment

Introduction

Ru Chih Huang is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of various cancers. With a total of 5 patents, his work focuses on innovative compositions and methods that aim to improve patient outcomes.

Latest Patents

Huang's latest patents include compositions comprising NDGA derivatives and sorafenib, which are utilized in the treatment of cancer. This invention provides pharmaceutical compositions that include derivatives of NDGA, such as M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib. These compositions are designed to inhibit and treat neoplastic diseases, including liver cancer, colon cancer, breast cancer, brain cancers, and ovarian cancers. Additionally, he has developed methods for the inhibition of BNIP3 and the prevention and treatment of ischemia-reperfusion injury in cardiac myocytes. This method involves administering a compound of formula I, or its derivatives, to mitigate or prevent injury to cardiac tissue during ischemic events.

Career Highlights

Ru Chih Huang is affiliated with The Johns Hopkins University, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on cancer treatment and cardiac health.

Collaborations

Huang collaborates with esteemed colleagues, including Kotohiko Kimura and Paul Edward Giza, to further enhance the scope and application of his inventions.

Conclusion

Ru Chih Huang's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through research and development. His patents reflect a dedication to addressing critical health challenges, particularly in oncology and cardiology.